Eupraxia Pharmaceuticals Inc. (EPRX) vs Rocket Pharmaceuticals, Inc. (RCKT)
A side-by-side comparison of Eupraxia Pharmaceuticals Inc. and Rocket Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EPRX
Eupraxia Pharmaceuticals Inc.
$7.82HealthcareDelayed quote: Oct 6, 2026, 2:15 PM EDT
RCKT
Rocket Pharmaceuticals, Inc.
$2.49HealthcareDelayed quote: Oct 6, 2026, 2:15 PM EDT
Total return — EPRX vs RCKT
growth of $100 · dividends reinvested · last 2yEPRX +162.7% (+62.1%/yr)RCKT -89.6% (-67.7%/yr)EPRX compounded faster over this window
Log scale — wide-divergence pair
EPRX RCKT
EPRX vs RCKT: by the numbers
- •RCKT is the larger company ($271M vs $262M market cap).
Metrics side by side
Valuation
| Metric | EPRX | RCKT |
|---|---|---|
| P/B ratio | 2.58 | 0.74 |
Profitability
| Metric | EPRX | RCKT |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -38.33% | -4.68% |
| ROIC | -43.56% | -48.92% |
Growth (annualized)
| Metric | EPRX | RCKT |
|---|---|---|
| Total return CAGR (5Y) | N/A | -38.33% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.